After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Akero Therapeutics Inc is $4.33B. A total of 1.42 million shares were traded on the day, compared to an average of 1.44M shares.
In the most recent transaction, Lamy Patrick sold 4,000 shares of AKRO for 50.31 per share on Jun 02 ’25. After the transaction, the Senior VP, Commercial Strategy now owns 33,492 company shares. In a previous transaction on May 22 ’25, Lamy Patrick sold 4,000 shares at 50.00 per share. AKRO shares that Senior VP, Commercial Strategy owns now total 33,492.
Among the insiders who bought shares, PATRICK D LAMY acquired of 10,000 shares on May 22 ’25 at a per-share price of $48.35. In another insider transaction, Yale Catriona sold 10,000 shares at $39.30 per share on May 15 ’25. Company shares held by the Chief Development Officer now total 95,034.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, AKRO has a high of $58.40 and a low of $20.34.
As of this writing, AKRO has an earnings estimate of -$0.86 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.97.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $13.60, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 5.00.
